Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Quidel Corporation (QDEL - Snapshot Report) received encouraging news when the U.S. Food and Drug Administration (FDA) cleared 510(k) for the sale of its AmpliVue Group B Strep Assay.

Quidel's non-instrumented molecular diagnostic test, AmpliVue, employs a novel amplification technology in the form of an easy-to-use, hand-held device.

AmpliVue Group B Strep Assay is the combination of isothermal Helicase Dependent Amplification (HDA) and Quidel’s expertise in lateral flow technology to detect Group B Streptococcus (GBS) from antepartum women.

Per the information provided by the Centers for Disease Control and Prevention (CDC), around 10%–30% of pregnant women carry GBS which can be transmitted to the newborn at the time of delivery.

AmpliVue Group B Strep assay is Quidel's second assay to launch in the hand-held, disposable AmpliVue format. The first was launched earlier this year for the detection of toxigenic Clostridium difficile bacterial DNA.

Quidel received 510(k) clearance from the FDA for the Sofia RSV Fluorescent Immunoassay (FIA) and the Sofia hCG Fluorescent Immunoassay (FIA) in Aug 2013. In Sep 2013, Quidel received 510(k) clearance for the Quidel Molecular Influenza A+B assay and the Quidel Molecular RSV + hMPV assay.

Both will be used for the Life Technologies Corp. flagship instrument QuantStudio Dx. QuantStudio Dx offers the advanced capabilities in flexible sample batching needed by higher-volume hospital and reference laboratories.

Quidel currently carries a Zacks Rank #2 (Buy). Another medical device stock worth a look is Cyberonics Inc. (CYBX - Analyst Report), which also carries a Zacks Rank #2. Investors may also consider BioLife Solutions, Inc. (BLFS), which carries a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%